StreetInsider.com News Articles

Journey Medical Corp. (DERM) PT Raised to $15 at B.Riley

Thu, 13 Aug 2026 08:59:25 -0400

B.Riley analyst Kalpit Patel raised the price target on Journey Medical Corp. (NASDAQ: DERM) to $15.00 (from $12.00) while maintaining a Buy rating.

Form 10-Q Journey Medical Corp For: Jun 30

Wed, 12 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26913702.html

Form 10-Q Journey Medical Corp For: Jun 30

Wed, 12 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260812/26913702.html

Dermira (DERM) Tops Q2 EPS by 12c

Wed, 12 Aug 2026 16:35:30 -0400

Dermira (NASDAQ: DERM) reported Q2 EPS of $0.10, $0.12 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $18.5 million versus the consensus estimate of $18.37 million.

For earnings history and earnings-related data on Dermira (DERM) click here.

Form 8-K Journey Medical Corp For: Aug 12

Wed, 12 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26912774.html

Form 8-K Journey Medical Corp For: Aug 12

Wed, 12 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260812/26912774.html

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

Wed, 05 Aug 2026 08:30:00 -0400